Guardant Health (FRA:5GH) Construction In Progress: €31.2 Mil (As of Mar. 2026)


FRA:5GH Guardant Health Inc FRA:5GH
67 GF Score
Price €134.86
GF Value €54.47
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guardant Health Construction In Progress?

Guardant Health FRA:5GH +1.44% 67 Construction In Progress is €31.2 Mil as of Mar. 2026. GuruFocus rates FRA:5GH with a GF Score™ of 67/100 and a GF Value™ of €54.47 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Guardant Health's quarterly construction in progress increased from Sep. 2025 (€18.2 Mil) to Dec. 2025 (€35.2 Mil) but then declined from Dec. 2025 (€35.2 Mil) to Mar. 2026 (€31.2 Mil).

Guardant Health's annual construction in progress increased from Dec. 2023 (€6.9 Mil) to Dec. 2024 (€26.9 Mil) and increased from Dec. 2024 (€26.9 Mil) to Dec. 2025 (€35.2 Mil).

Guardant Health Construction In Progress Historical Data

* Premium members only.

The historical data trend for Guardant Health's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health Construction In Progress Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.45 19.45 6.89 26.87 35.23

Guardant Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.59 18.10 18.22 35.23 31.20
FRA:5GH
67GF Score
Guardant Health Inc FRA:5GH
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guardant Health Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €31.2 Mil mean?
Guardant Health (FRA:5GH) has a Construction In Progress of €31.2 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Guardant Health and its competitors.
Is Guardant Health's Construction In Progress too high?
Guardant Health's current Construction In Progress is €31.2 Mil. Overall, Guardant Health has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Construction In Progress compare to LH and DGX?
Guardant Health's Construction In Progress of €31.2 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Diagnostics & Research company?
A good Construction In Progress depends on the Medical Diagnostics & Research industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Guardant Health and its competitors. Guardant Health's current Construction In Progress is €31.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (FRA:5GH) is currently considered Significantly Overvalued. The stock's GF Value™ is €54.47, compared to a current price of €134.86 — trading 147.6% above its estimated fair value. The current Construction In Progress is €31.2 Mil. Guardant Health's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Guardant Health (FRA:5GH), the current Construction In Progress is €31.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guardant Health (FRA:5GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €134.86 is trading 147.6% above its estimated GF Value™ of €54.47. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for FRA:5GH:

  • Construction In Progress: €31.2 Mil
  • GF Value™: €54.47 vs. price of €134.86 (147.6% above fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the FRA:5GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
67GF Score

Get the complete analysis for FRA:5GH

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.86
Price
€54.47
GF Value